205 related articles for article (PubMed ID: 22152119)
1. Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis.
Anand RS; Somasundaram S; Doble M; Paramasivan CN
BMC Struct Biol; 2011 Dec; 11():47. PubMed ID: 22152119
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
Von Groll A; Martin A; Jureen P; Hoffner S; Vandamme P; Portaels F; Palomino JC; da Silva PA
Antimicrob Agents Chemother; 2009 Oct; 53(10):4498-500. PubMed ID: 19687244
[TBL] [Abstract][Full Text] [Related]
3. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
[TBL] [Abstract][Full Text] [Related]
4. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Poissy J; Aubry A; Fernandez C; Lott MC; Chauffour A; Jarlier V; Farinotti R; Veziris N
Antimicrob Agents Chemother; 2010 Nov; 54(11):4765-71. PubMed ID: 20805388
[TBL] [Abstract][Full Text] [Related]
5. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
Fillion A; Aubry A; Brossier F; Chauffour A; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2013 Sep; 57(9):4496-500. PubMed ID: 23836169
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis.
Pandey B; Grover S; Tyagi C; Goyal S; Jamal S; Singh A; Kaur J; Grover A
J Biomol Struct Dyn; 2018 Feb; 36(2):362-375. PubMed ID: 28071975
[TBL] [Abstract][Full Text] [Related]
7. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis.
Pantel A; Petrella S; Veziris N; Brossier F; Bastian S; Jarlier V; Mayer C; Aubry A
Antimicrob Agents Chemother; 2012 Apr; 56(4):1990-6. PubMed ID: 22290942
[TBL] [Abstract][Full Text] [Related]
8. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
van der Heijden YF; Maruri F; Blackman A; Mitchel E; Bian A; Shintani AK; Eden S; Warkentin JV; Sterling TR
Int J Antimicrob Agents; 2013 Sep; 42(3):232-7. PubMed ID: 23806638
[TBL] [Abstract][Full Text] [Related]
9. Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Disratthakit A; Prammananan T; Tribuddharat C; Thaipisuttikul I; Doi N; Leechawengwongs M; Chaiprasert A
Antimicrob Agents Chemother; 2016 Sep; 60(9):5189-97. PubMed ID: 27297489
[TBL] [Abstract][Full Text] [Related]
10. Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis.
Luo T; Yuan J; Peng X; Yang G; Mi Y; Sun C; Wang C; Zhang C; Bao L
J Antimicrob Chemother; 2017 Jul; 72(7):1893-1900. PubMed ID: 28387828
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
Spigaglia P; Barbanti F; Louie T; Barbut F; Mastrantonio P
Antimicrob Agents Chemother; 2009 Jun; 53(6):2463-8. PubMed ID: 19364867
[TBL] [Abstract][Full Text] [Related]
12. Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
De Azavedo JC; Duncan CL; Kilburn L; Downar J; Kong B; Lad S; Low DE; Bast DJ
J Chemother; 2006 Aug; 18(4):373-8. PubMed ID: 17024792
[TBL] [Abstract][Full Text] [Related]
13. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
[TBL] [Abstract][Full Text] [Related]
14. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
Sirgel FA; Warren RM; Streicher EM; Victor TC; van Helden PD; Böttger EC
J Antimicrob Chemother; 2012 May; 67(5):1088-93. PubMed ID: 22357804
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
Yamada M; Yoshida J; Hatou S; Yoshida T; Minagawa Y
Br J Ophthalmol; 2008 Jun; 92(6):848-51. PubMed ID: 18460536
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.
Aldred KJ; Blower TR; Kerns RJ; Berger JM; Osheroff N
Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E839-46. PubMed ID: 26792518
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.
Matrat S; Veziris N; Mayer C; Jarlier V; Truffot-Pernot C; Camuset J; Bouvet E; Cambau E; Aubry A
Antimicrob Agents Chemother; 2006 Dec; 50(12):4170-3. PubMed ID: 17015625
[TBL] [Abstract][Full Text] [Related]
18. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.
Cheng AF; Yew WW; Chan EW; Chin ML; Hui MM; Chan RC
Antimicrob Agents Chemother; 2004 Feb; 48(2):596-601. PubMed ID: 14742214
[TBL] [Abstract][Full Text] [Related]
19. Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.
Sayadi M; Zare H; Jamedar SA; Hashemy SI; Meshkat Z; Soleimanpour S; Hoffner S; Ghazvini K
BMC Infect Dis; 2020 Jun; 20(1):390. PubMed ID: 32487030
[TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Garrison MW; Schimmels JA; Madaras-Kelly KJ
Diagn Microbiol Infect Dis; 2003 Dec; 47(4):587-93. PubMed ID: 14711480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
